{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:46:59Z","timestamp":1783745219471,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The TuberOus SClerosis registry to increase disease Awareness (TOSCA) Post-Authorization Safety Study (PASS) was a non-interventional, multicenter, safety substudy that assessed the long-term safety of everolimus in patients with tuberous sclerosis complex (TSC) receiving everolimus for its licensed indications in the European Union (EU). This substudy also aimed to address TSC-associated neuropsychiatric disorders (TAND), sexual development, and male infertility. Eligible patients were enrolled from 39 sites across 11 countries in the EU. Outcomes of interest included the incidence of adverse events (AEs), serious adverse events (SAEs), treatment-related AEs (TRAEs), AEs leading to everolimus discontinuation, AEs of special interest (AESIs), the observed relationship between everolimus blood levels and incidence of AESIs, TAND, and reproductive clinical features. Herein, we present the final analysis results from this substudy (data cutoff date: 22 January 2020). At data cutoff, 179 patients were enrolled (female, 59.2%; age \u226518\u00a0years, 65.9%), of which the majority completed the study (76%). Overall, 121 patients (67.6%) had AEs regardless of causality. The most frequent TRAEs (\u22655%) were stomatitis (7.8%), aphthous ulcer (6.7%), and hypercholesterolemia (6.1%). The most common treatment-related SAEs (&amp;gt;1%) were pneumonia (3.4%), influenza, pyelonephritis, aphthous ulcer, stomatitis, dyslipidemia, and hypercholesterolemia (1.1% each). Ten patients (5.6%) reported AEs leading to everolimus discontinuation. The common psychiatric disorders (<jats:italic>N<\/jats:italic> = 179) were autism spectrum disorder (21.8%), anxiety disorder (12.8%), \u201cother\u201d psychiatric disorders (8.9%), attention-deficit hyperactivity disorder, and depressive disorder (7.8% each). Of 179 patients, 88 (49.2%) had \u22651 behavioral problem. Of these (<jats:italic>n<\/jats:italic> = 88), the most common (&amp;gt;20%) were sleep difficulties (47.7%), anxiety (43.2%), mood swings (37.5%), depression mood (35.2%), impulsivity (30.7%), severe aggression (23.9%), and overactivity (22.7%). Of 179 patients, four (2.2%) reported abnormal puberty onset, and three (1.7%) reported other reproductive disorders. Of 106 females, 23 (21.7%) reported menstrual cycle disorders and 10 (9.4%) reported amenorrhea. Available data did not show delays in sexual maturation or an association between sexual development and infertility. The results demonstrate that everolimus has a manageable long-term safety profile in the TSC treatment setting. No new safety signals emerged. This substudy also contributed to the mapping of TAND and reproductive clinical features in patients with TSC.<\/jats:p>","DOI":"10.3389\/fphar.2022.802334","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T04:27:22Z","timestamp":1649392042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results"],"prefix":"10.3389","volume":"13","author":[{"given":"Mar\u00eda Luz","family":"Ruiz-Falc\u00f3 Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons","family":"Macaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wilken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Maamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Hirschberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Chris","family":"Kingswood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3389\/fneur.2019.01116","article-title":"Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care","volume":"10","author":"Annear","year":"2019","journal-title":"Front. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus Long-Term Use in Patients with Tuberous Sclerosis Complex: Four-Year Update of the EXIST-2 Study","volume":"12","author":"Bissler","year":"2017","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for Renal Angiomyolipoma in Patients with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Extension of a Randomized Controlled Trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for Angiomyolipoma Associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): a Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-4632.2010.04727.x","article-title":"Tuberous Sclerosis Complex: Tumors and Tumorigenesis","volume":"50","author":"Borkowska","year":"2011","journal-title":"Int. J. Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2147\/NDT.S91248","article-title":"Profile of Everolimus in the Treatment of Tuberous Sclerosis Complex: an Evidence-Based Review of its Place in Therapy","volume":"12","author":"Capal","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The Tuberous Sclerosis Complex","volume":"355","author":"Crino","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous Sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/B978-0-444-52891-9.00038-5","article-title":"Tuberous Sclerosis","volume":"111","author":"Curatolo","year":"2013","journal-title":"Handb Clin. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and Neuropsychiatric Aspects of Tuberous Sclerosis Complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: a Phase 2 Trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13023-017-0581-9","article-title":"Management of Everolimus-Associated Adverse Events in Patients with Tuberous Sclerosis Complex: a Practical Guide","volume":"12","author":"Davies","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13023-018-0901-8","article-title":"TSC-associated Neuropsychiatric Disorders (TAND): Findings from the TOSCA Natural History Study","volume":"13","author":"de Vries","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"B16","volume-title":"Votubia : EPAR - Product Information","author":"European Medicines Agency","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for Subependymal Giant Cell Astrocytoma in Patients with Tuberous Sclerosis Complex: 2-year Open-Label Extension of the Randomised EXIST-1 Study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and Safety of Everolimus for Subependymal Giant Cell Astrocytomas Associated with Tuberous Sclerosis Complex (EXIST-1): a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-0030-1269906","article-title":"Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations","volume":"41","author":"Franz","year":"2010","journal-title":"Neuropediatrics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ajmg.c.31655","article-title":"mTOR Inhibitor Therapy as a Disease Modifying Therapy for Tuberous Sclerosis Complex","volume":"178","author":"Franz","year":"2018","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","article-title":"Everolimus for Treatment-Refractory Seizures in TSC: Extension of a Randomized Controlled Trial","volume":"8","author":"Franz","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive Everolimus Therapy for Treatment-Resistant Focal-Onset Seizures Associated with Tuberous Sclerosis (EXIST-3): a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 Complex: a Molecular Switchboard Controlling Cell Growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem. J."},{"key":"B25","first-page":"25","article-title":"Tuberous Sclerosis Complex and Renal Angiomyolipomas","volume":"22","author":"Iqbal","year":"2017","journal-title":"Br. J. Ren. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fneur.2020.00904","article-title":"Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings from the TOSCA Study","volume":"11","author":"Jansen","year":"2020","journal-title":"Front. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1470-2045(07)70411-4","article-title":"Possible Mechanisms of Disease Development in Tuberous Sclerosis","volume":"9","author":"Jozwiak","year":"2008","journal-title":"Lancet Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/088307380001501003","article-title":"Usefulness of Diagnostic Criteria of Tuberous Sclerosis Complex in Pediatric Patients","volume":"15","author":"J\u00f3zwiak","year":"2000","journal-title":"J. Child. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13023-014-0182-9","article-title":"TOSCA - First International Registry to Address Knowledge Gaps in the Natural History and Management of Tuberous Sclerosis Complex","volume":"9","author":"Kingswood","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","article-title":"TuberOus SClerosis Registry to Increase Disease Awareness (TOSCA) - Baseline Data on 2093 Patients","volume":"12","author":"Kingswood","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fneur.2021.630378","article-title":"TuberOus SClerosis Registry to increAse Disease Awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients with Tuberous Sclerosis Complex","volume":"12","author":"Kingswood","year":"2021","journal-title":"Front. Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus Long-Term Safety and Efficacy in Subependymal Giant Cell Astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"R251","DOI":"10.1093\/hmg\/ddi260","article-title":"Tuberous Sclerosis: a GAP at the Crossroads of Multiple Signaling Pathways","volume":"14","author":"Kwiatkowski","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1177\/08830738040190090601","article-title":"Behavioral and Cognitive Aspects of Tuberous Sclerosis Complex","volume":"19","author":"Prather","year":"2004","journal-title":"J. Child. Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2014.10.024","article-title":"Long-Term Everolimus Treatment in Individuals with Tuberous Sclerosis Complex: A Review of the Current Literature","volume":"53","author":"Tran","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","article-title":"Complications of Mammalian Target of Rapamycin Inhibitor Anticancer Treatment Among Patients with Tuberous Sclerosis Complex Are Common and Occasionally Life-Threatening","volume":"26","author":"Trelinska","year":"2015","journal-title":"Anticancer Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1005637","DOI":"10.1371\/journal.pgen.1005637","article-title":"Mosaic and Intronic Mutations in TSC1\/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing","volume":"11","author":"Tyburczy","year":"2015","journal-title":"Plos Genet."},{"key":"B41","volume-title":"Everolimus Prescribing Information","author":"Us Food and Drug Administration","year":"2018"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1172\/JCI17222","article-title":"Loss of Tsc1\/Tsc2 Activates mTOR and Disrupts PI3K-Akt Signaling through Downregulation of PDGFR","volume":"112","author":"Zhang","year":"2003","journal-title":"J. Clin. Invest."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.802334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T04:27:27Z","timestamp":1649392047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.802334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":42,"alternative-id":["10.3389\/fphar.2022.802334"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.802334","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"article-number":"802334"}}